Implementing Cardiovascular Risk Reduction in Patients with Cardiovascular Disease and Diabetes Mellitus

Nandish, Shailesh; Wyatt, Jamison; Bailon, Oscar; Smith, Mike; Oliveros, Rene A; Chilton, Robert

doi:10.1016/j.amjcard.2011.03.015

Cited by 28 publications

(22 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, data analysis by other investigators found equal effectiveness of OMT or PCI revascularization strategy in physical and psychological recovery of T2DM patients (17). More recently, subanalysis of the BARI-2D findings reported that rosiglitazone therapy, compared with no TZD therapy, was not associated with an excess risk of MI or stroke in the trial (114). Conclusions of the BARI-2D study substantially overlapped those of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation trial (14), which was designed to evaluate whether association of PCI to OMT is superior to OMT alone in reducing the risk of cardiovascular events in diabetic patients with stable CAD.…”

Section: Molecular and Cellular Properties Of Rosiglitazonementioning

confidence: 93%

Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology

Sgarra

Addabbo

Potenza

et al. 2012

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

Rosiglitazone is a thiazolidinedione, a synthetic PPARγ receptor agonist with insulin-sensitizing properties that is used as an antidiabetic drug. In addition to improving glycemic control through actions in metabolic target tissues, rosiglitazone has numerous biological actions that impact on cardiovascular homeostasis. Some of these actions are helpful (e.g., improving endothelial function), whereas others are potentially harmful (e.g., promoting fluid retention). Since cardiovascular morbidity and mortality are major endpoints for diabetes, it is essential to understand how the natural history of diabetes alters the net benefits and risks of rosiglitazone therapy. This complex issue is an important determinant of optimal use of rosiglitazone and is critical for understanding cardiovascular safety issues. We give special attention to the effects of rosiglitazone in diabetic patients with stable coronary artery disease and the impact of rosiglitazone actions on atherosclerosis and plaque instability. This provides a rational conceptual framework for predicting evolving benefit/risk profiles that inform optimal use of rosiglitazone in the clinical setting and help explain the results of recent large clinical intervention trials where rosiglitazone had disappointing cardiovascular outcomes. Thus, in this perspective, we describe what is known about the molecular mechanisms of action of rosiglitazone on cardiovascular targets in the context of the evolving pathophysiology of diabetes over its natural history.

show abstract

Section: Molecular and Cellular Properties Of Rosiglitazonementioning

confidence: 93%

Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology

Sgarra

Addabbo

Potenza

et al. 2012

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

show abstract

“…Improved fitness is strongly associated with a reduction in the risk of developing coronary heart disease, and a reduction in mortality risk [2,3]. Moreover, the improvements in strength, agility and flexibility promote better performance in activities of daily living [4], positively impacting the participant´s quality of life.…”

Section: Discussionmentioning

confidence: 99%

“…A healthy lifestyle -including regular physical activity, a balanced diet, and weight management -is the best way to prevent and treat CVD [3]. The American College of Sports Medicine (ACSM) recommends that most adults engage in moderate-intensity cardiorespiratory exercise training for ≥ 30 min/day −1 on ≥ 5 days.week −1 , or a vigorousintensity cardiorespiratory exercise training for ≥ 20 min.day −1 on ≥ 3 days.week −1 , or a combination of both [4].…”

Section: Introductionmentioning

confidence: 99%

A tennis-based health program for middle-aged men who are at risk for heart disease

Rosa¹,

Fuentes-García²,

Remor³

et al. 2017

Integr Obesity Diabetes

View full text Add to dashboard Cite

The purpose of this study was to investigate the health effects of an adapted tennis-based exercise program, in middle-aged men with moderate risk of cardiovascular diseases (CVD). Fifteen men (44.9 ± 4.9 years) with two or more CVD risk factors, completed an eight-week health program that included a continuous tennisbased exercise protocol with constant and controlled intensity between 70%-85% of maximum heart rate and a standard nutritional orientation. Participants were assessed at the beginning and end of the exercise program for standard parameters related to CVD and the Framingham risk score, motor skills and cardiopulmonary fitness, peripheral inflammation (neopterin levels), oxidative stress (nitric oxide and carbonylated protein content), and mitochondrial function (lymphocyte complex I activity). Exercise improved muscle strength and power, speed, agility and flexibility, V O 2 max and metabolic equivalents. The participants experienced decreases in body mass index, waist circumference, total and LDL-cholesterol, and reduction in the Framingham Risk Score. Exercise also decreased peripheral oxidative stress and production of nitric oxide. In addition, the increased V O 2 at ventilatory threshold 1 correlated with enhanced mitochondrial activity in blood lymphocytes. The tennis-based exercise program adapted to sustaining moderate and constant intensity represents a valuable non-pharmacological intervention to prevent CVD.speed, muscle power and endurance, among others. Outdoor sports are motivating and enjoyable with high adherence levels [6].

show abstract

“…3 Diagnosis of diabetes is correlated with a 10-to 15-year reduction in lifespan. 4 With such a staggering prevalence, it is imperative to reduce the complications that result from longstanding and uncontrolled hyperglycemia. In addition to the known microvascular complications (ie, nephropathy, neuropathy, and retinopathy), patients with diabetes also experience cardiovascular disease (CVD) complications.…”

Section: Introductionmentioning

confidence: 99%

Diabetes Pharmacotherapy in 2012: Considerations in Medication Selection

Cornell

Dorsey

2012

Postgraduate Medicine

View full text Add to dashboard Cite

Diabetes is one of the most costly and burdensome chronic diseases, and its therapy and management have become increasingly complex. The incidence of type 2 diabetes mellitus (T2DM), a multiorgan disorder, is increasing at an epidemic rate in the United States and worldwide. Despite numerous scientific and medical advances, less than half of the population with T2DM has achieved the American Diabetes Association-recommended glycated hemoglobin level goal of < 7%, which is necessary to optimally manage the disease to prevent and minimize complications. There are many patient- and clinician-determined barriers that hinder patients from achieving target blood glucose levels. Therefore, it is imperative for health care professionals who treat patients with T2DM (and those at risk for developing T2DM) to have an enhanced knowledge base of the current pathophysiology, treatment options, and clinical guidelines for T2DM and its related conditions.

show abstract

Implementing Cardiovascular Risk Reduction in Patients with Cardiovascular Disease and Diabetes Mellitus

Cited by 28 publications

References 45 publications

Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology

Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology

A tennis-based health program for middle-aged men who are at risk for heart disease

Diabetes Pharmacotherapy in 2012: Considerations in Medication Selection

Contact Info

Product

Resources

About